Skip to main
ATOS
ATOS logo

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc is positioned favorably due to its focus on developing proprietary medicines targeting areas of high unmet medical need, notably in oncology and COVID-19. The company's ongoing development of Endoxifen for breast cancer, coupled with its promising COVID-19 therapies, AT-H201 and AT-301, highlights its commitment to innovative therapeutics, which could serve as significant growth drivers. Current analyses indicate an attractive valuation, suggesting potential upside, particularly as the company approaches key clinical milestone achievements that are expected to act as catalysts for stock performance.

Bears say

Atossa Therapeutics Inc reported a net loss of $8.4 million, resulting in an earnings per share (EPS) of $(0.07), which was below both company and consensus estimates of $(0.06). The company faces several significant risks, including balance sheet and liquidity concerns, the potential failure of its product candidates to prove safety and efficacy in clinical trials, and challenges related to regulatory approvals and commercialization. Additionally, external factors such as market competition, changing macroeconomic conditions, and fluctuating investor sentiment toward biotech stocks further contribute to a negative outlook for the company.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.